Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Gw Research Limited manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 matters are assigned to 3 distinct examiners and 3 distinct art units. This one-to-one ratio between the 3 pending office actions and the 3 distinct examiners shows a decentralized prosecution landscape. Each application is being evaluated by a different technical specialist in a different USPTO group.
FOWLER, ALAN JEROME is the busiest examiner for the portfolio, with 1 pending office action. Because each of the 3 pending matters is handled by a different examiner in a different art unit, the company must manage 3 separate prosecution tracks. Each of the 3 distinct examiners will apply the specific standards of their respective art units to the applications. Practitioners should tailor their arguments to the individual preferences of FOWLER, ALAN JEROME.
The lack of concentration across the 3 distinct art units reduces the risk that a single adverse trend will affect the entire portfolio. However, it also requires the company to be responsive to the diverse feedback from 3 different examiners. Success in the Biotechnology & Pharmaceuticals sector for this company depends on effectively navigating the unique requirements of each of the 3 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| TRAN, ERIC | 1 | 69.8% | +19.4% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560346 | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | FOWLER, ALAN JEROME | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17606370 | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | TRAN, ERIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17606370 | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | TRAN, ERIC | — |
| 16935005 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | BAEK, BONG-SOOK | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1629 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560346 | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | FOWLER, ALAN JEROME | 1691 | §103Other | Non-Final OA | — | Pending | Nov 10, 2023 |
| 17606370 | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | TRAN, ERIC | 1629 | §103§112 | Non-Final OA | — | Pending | Oct 25, 2021 |
| 16935005 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | BAEK, BONG-SOOK | 1611 | §103DP | Final Rejection | — | Pending | Jul 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGw Research Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Alan Jerome Fowler has the most, with 1 of Gw Research Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
